Literature DB >> 29595502

Pan-tuberculosis regimens: an argument against.

Keertan Dheda1, Tawanda Gumbo2, Christoph Lange3, C Robert Horsburgh4, Jennifer Furin5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29595502     DOI： 10.1016/S2213-2600(18)30097-3

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  5 in total

Review 1.  Would pan-tuberculosis treatment regimens be cost-effective?

Authors:  Emily A Kendall; Grania Brigden; Christian Lienhardt; David W Dowdy
Journal:  Lancet Respir Med       Date:  2018-05-31       Impact factor: 30.700

2.  Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration.

Authors:  Tawanda Gumbo; Carleton M Sherman; Devyani Deshpande; Jan-Willem Alffenaar; Shashikant Srivastava
Journal:  Int J Infect Dis       Date:  2021-02-05       Impact factor: 3.623

Review 3.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

4.  Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.

Authors:  Helen Cox; Galo A Goig; Zubeida Salaam-Dreyer; Anzaan Dippenaar; Anja Reuter; Erika Mohr-Holland; Johnny Daniels; Patrick G T Cudahy; Mark P Nicol; Sonia Borrell; Miriam Reinhard; Anna Doetsch; Christian Beisel; Sebastien Gagneux; Robin M Warren; Jennifer Furin
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 5.948

5.  The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.

Authors:  Nimalan Arinaminpathy; Gabriela B Gomez; Kuldeep S Sachdeva; Raghuram Rao; Malik Parmar; Sreenivas A Nair; Kiran Rade; Sameer Kumta; David Hermann; Christy Hanson; Daniel P Chin; Puneet Dewan
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.